Humira's approval widened to include ulcerative colitis

Humira's approval widened to include ulcerative colitis

(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.

Humira—an anti- agent that's designed to suppress abnormal inflammatory and immune responses—has already been approved to treat a host of conditions, including , Crohn's disease, and plaque psoriasis.

Ulcerative colitis affects about 620,000 people in the United States, according to the U.S. National Institutes of Health.

The most common side effects of Humira include infection, injection-site reaction, headache, and rash, according to an FDA news release.

The drug is manufactured by Abbott Laboratories, based in North Chicago, Ill.

More information: The U.S. National Library of Medicine has more about ulcerative colitis.

add to favorites email to friend print save as pdf

Related Stories

Pfizer says patient died in oral RA drug study

Apr 22, 2011

(AP) -- Pfizer Inc. confirmed that one patient who was taking its drug candidate tofacitinib, a pill designed to treat rheumatoid arthritis, died during a recent clinical trial and said the death was connected to the drug.

FDA: Arthritis drugs pose cancer risk to children

Aug 04, 2009

(AP) -- Federal regulators on Tuesday added stronger warnings to a group of best-selling drugs used to treat arthritis and other inflammatory diseases, saying they can increase the risk of cancer in children and adolescents.

Marqibo approved for ph- acute lymphoblastic leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

22 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments